Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Consolidated Net Income: 2014-2024

Historic Consolidated Net Income for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to -$65.0 million.

  • Voyager Therapeutics' Consolidated Net Income fell 208.40% to -$27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.8 million, marking a year-over-year decrease of 589.88%. This contributed to the annual value of -$65.0 million for FY2024, which is 149.12% down from last year.
  • Voyager Therapeutics' Consolidated Net Income amounted to -$65.0 million in FY2024, which was down 149.12% from $132.3 million recorded in FY2023.
  • In the past 5 years, Voyager Therapeutics' Consolidated Net Income registered a high of $132.3 million during FY2023, and its lowest value of -$71.2 million during FY2021.
  • In the last 3 years, Voyager Therapeutics' Consolidated Net Income had a median value of -$46.4 million in 2022 and averaged $7.0 million.
  • As far as peak fluctuations go, Voyager Therapeutics' Consolidated Net Income crashed by 293.78% in 2021, and later spiked by 385.14% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' Consolidated Net Income stood at $36.7 million in 2020, then slumped by 293.78% to -$71.2 million in 2021, then spiked by 34.82% to -$46.4 million in 2022, then skyrocketed by 385.14% to $132.3 million in 2023, then tumbled by 149.12% to -$65.0 million in 2024.